Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

15987.2;3 PFLS-LS

Titre du projet

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Titre du projet anglais

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders
Résumé des résultats (Abstract) (Anglais)	The project objective is the design, synthesis and pharmacological characterization of a series of novel compounds that are potent and selective inverse agonists of the ghrelin receptor. Ghrelin antagonism/inverse agonism is considered a valid treatment paradigm for obesity, type 2 diabetes and metabolic syndrome. The ultimate goal is to obtain preclinical candidates that could lead to the development of innovative medicines for these pathological conditions.

Catégorie

Texte

Description succincte
(Anglais)

Design, Synthesis and Pharmacological Characterization of Novel, Potent and Selective Ghrelin Receptor Inverse Agonists for Potential Use in Obesity Associated Metabolic Disorders

Résumé des résultats (Abstract)
(Anglais)

The project objective is the design, synthesis and pharmacological characterization of a series of novel compounds that are potent and selective inverse agonists of the ghrelin receptor. Ghrelin antagonism/inverse agonism is considered a valid treatment paradigm for obesity, type 2 diabetes and metabolic syndrome. The ultimate goal is to obtain preclinical candidates that could lead to the development of innovative medicines for these pathological conditions.